Therapeutic angiogenesis: Recent and future prospects of gene therapy in peripheral artery disease

Michiko Tanaka, Kikuko Taketomi, Yoshikazu Yonemitsu

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Peripheral artery disease (PAD) is a highly prevalent disease, which still has unmet medical needs. Therapeutic angiogenesis for PAD, achieved by gene therapy, has achieved promising results in preclinical studies and early-phase clinical trials, yet few late-phase clinical trials have been conducted or have not shown efficacy. This article provides an overview of the progression of angiogenesis research in gene therapy field as it applies to PAD. The focus of angiogenic growth factors and clinical trials is introduced as a frontier of therapeutic angiogenesis. The article also includes insights into future directions from bench to bedside.

Original languageEnglish
Pages (from-to)300-308
Number of pages9
JournalCurrent Gene Therapy
Volume14
Issue number4
DOIs
Publication statusPublished - Sep 1 2014

Fingerprint

Peripheral Arterial Disease
Genetic Therapy
Clinical Trials
Angiogenesis Inducing Agents
Intercellular Signaling Peptides and Proteins
Therapeutics
Research

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Drug Discovery
  • Genetics(clinical)

Cite this

Therapeutic angiogenesis : Recent and future prospects of gene therapy in peripheral artery disease. / Tanaka, Michiko; Taketomi, Kikuko; Yonemitsu, Yoshikazu.

In: Current Gene Therapy, Vol. 14, No. 4, 01.09.2014, p. 300-308.

Research output: Contribution to journalArticle

@article{c8323a6212d14dc6a0b4e5b552118b1b,
title = "Therapeutic angiogenesis: Recent and future prospects of gene therapy in peripheral artery disease",
abstract = "Peripheral artery disease (PAD) is a highly prevalent disease, which still has unmet medical needs. Therapeutic angiogenesis for PAD, achieved by gene therapy, has achieved promising results in preclinical studies and early-phase clinical trials, yet few late-phase clinical trials have been conducted or have not shown efficacy. This article provides an overview of the progression of angiogenesis research in gene therapy field as it applies to PAD. The focus of angiogenic growth factors and clinical trials is introduced as a frontier of therapeutic angiogenesis. The article also includes insights into future directions from bench to bedside.",
author = "Michiko Tanaka and Kikuko Taketomi and Yoshikazu Yonemitsu",
year = "2014",
month = "9",
day = "1",
doi = "10.2174/156652321404140902124838",
language = "English",
volume = "14",
pages = "300--308",
journal = "Current Gene Therapy",
issn = "1566-5232",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Therapeutic angiogenesis

T2 - Recent and future prospects of gene therapy in peripheral artery disease

AU - Tanaka, Michiko

AU - Taketomi, Kikuko

AU - Yonemitsu, Yoshikazu

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Peripheral artery disease (PAD) is a highly prevalent disease, which still has unmet medical needs. Therapeutic angiogenesis for PAD, achieved by gene therapy, has achieved promising results in preclinical studies and early-phase clinical trials, yet few late-phase clinical trials have been conducted or have not shown efficacy. This article provides an overview of the progression of angiogenesis research in gene therapy field as it applies to PAD. The focus of angiogenic growth factors and clinical trials is introduced as a frontier of therapeutic angiogenesis. The article also includes insights into future directions from bench to bedside.

AB - Peripheral artery disease (PAD) is a highly prevalent disease, which still has unmet medical needs. Therapeutic angiogenesis for PAD, achieved by gene therapy, has achieved promising results in preclinical studies and early-phase clinical trials, yet few late-phase clinical trials have been conducted or have not shown efficacy. This article provides an overview of the progression of angiogenesis research in gene therapy field as it applies to PAD. The focus of angiogenic growth factors and clinical trials is introduced as a frontier of therapeutic angiogenesis. The article also includes insights into future directions from bench to bedside.

UR - http://www.scopus.com/inward/record.url?scp=84907152765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907152765&partnerID=8YFLogxK

U2 - 10.2174/156652321404140902124838

DO - 10.2174/156652321404140902124838

M3 - Article

C2 - 25197884

AN - SCOPUS:84907152765

VL - 14

SP - 300

EP - 308

JO - Current Gene Therapy

JF - Current Gene Therapy

SN - 1566-5232

IS - 4

ER -